The trial aimed to evaluate the efficacy of delayed initiation of Olaparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer. The market for PARP inhibitors, particularly in ovarian cancer, is significant, with increasing competition from other therapies. The slow enrollment leading to trial termination raises concerns about patient recruitment strategies and the potential for market saturation. Companies should assess the competitive landscape, particularly with other PARP inhibitors and emerging therapies targeting similar patient populations. Diligence should focus on understanding the implications of delayed treatment initiation on patient outcomes and healthcare costs.